A Novel HER2-Selective Kinase Inhibitor Is Effective in HER2 Mutant and Amplified Non-Small Cell Lung Cancer.
Son, J., Jang, J., Beyett, T.S., Eum, Y., Haikala, H.M., Verano, A., Lin, M., Hatcher, J.M., Kwiatkowski, N.P., Eser, P.O., Poitras, M.J., Wang, S., Xu, M., Gokhale, P.C., Cameron, M.D., Eck, M.J., Gray, N.S., Janne, P.A.(2022) Cancer Res 82: 1633-1645
- PubMed: 35149586 
- DOI: 10.1158/0008-5472.CAN-21-2693
- Primary Citation of Related Structures:  
7JXH - PubMed Abstract: 
In-frame insertions in exon 20 of HER2 are the most common HER2 mutations in patients with non-small cell lung cancer (NSCLC), a disease in which approved EGFR/HER2 tyrosine kinase inhibitors (TKI) display poor efficiency and undesirable side effects due to their strong inhibition of wild-type (WT) EGFR ...